Table 2. Univariate Cox regression analysis of patient’s characteristics.

	Hazard ratio	CI 95%	p-value
Clinical characteristics
age, per year	1.00	0.97–1.03	0.79
masculine sex, yes vs no	1.25	0.74–2.10	0.41
Multiple myeloma stages and treatment
Salmon & Durie stages
1	1.00	0.50–2.03	1.00
2	0.62	0.30–1.26	0.19
3	1.42	0.82–2.49	0.20
stage B, yes vs no	2.37	1.38–4.07	0.002
bortezomib-based induction, yes vs no	0.99	0.31–3.20	0.99
IMiD-based induction, yes vs no	0.39	0.53–2.81	0.27
Non novel agent-based, yes vs no	1.42	0.51–3.92	0.50
Clinical examination
peripheral edema, yes vs no	0.90	0.32–2.51	0.84
rest dyspnea, yes vs no	8.91	2.12–37.4	0.003
Cardiovascular risk factors
Body Mass Index> 30kg/m, yes vs no	1.19	0.51–2.78	0.69
Arterial hypertension1, yes vs no	1.93	1.11–3.36	0.02
diagnosis before induction	1.76	1.05–2.94	0.03
antihypertensive therapy	1.76	1.05–2.98	0.03
blood pressure > 140/90 mmHg before induction	1.25	0.73–2.14	0.43
smoking history, yes vs no	1.98	1.10–3.58	0.02
diabetes mellitus, yes vs no	0.88	0.32–2.44	0.80
hyperlipidemia, yes vs no	1.15	0.54–2.45	0.72
positive family history, yes vs no	7.00	0.96–51.2	0.06
co-morbidities
heart failure, yes vs no	1.83	0.44–7.58	0.40
coronary artery disease, yes vs no	1.05	0.26–4.34	0.94
peripheral artery occlusive disease, yes vs no	12.63	2.92–54.5	0.001
pulmonary diseases, yes vs no	2.35	0.84–6.56	0.10
renal insufficiency, yes vs no	2.03	1.19–3.47	0.01
anemia, yes vs no	2.06	1.07–3.96	0.03

All variables of Table 1 were tested; associations with p ≤ 0.05 are marked (bold print). Abbreviations and definitions as in Table 1.